Affiliations: Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
Correspondence:
[*]
Corresponding authors: Shi-Yong Yang and Kun-Xing Yang, Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. E-mail: hrbyong@sina.com,yangkunxing@medmail.com.cn
Abstract:
BACKGROUND: MicroRNA-145 (miR-145) plays a crucial role in cancer
prognosis. OBJECTIVE: This study aimed to investigate the prognostic value of
miR-145 in patients with various cancers. METHODS: We pooled published literature from PubMed, EMBASE, Web of
Science and Cochrane Database of Systematic Reviews and calculated the
hazard ratios (HRs) with 95% confidence intervals (CIs) to estimate the
correlation between miR-145 expression levels and survival of patients with
general cancers. RESULTS: A total of 615 cases from 8 studies of multiple cancers
were examined in this meta-analysis. The HR for overall survival (OS) of low
miR-145 expression in multiple cancers was 1.80 (95% CI = 1.19-2.70).
Furthermore, after excluding 1 study for its potential heterogeneity, the
results suggested an increasing prognostic value of low miR-145 expression
(HR = 2.20, 95% CI = 1.63-1.97). In addition, there was no significant
difference between miR-145 expression levels and recurrence-free survival
(RFS). CONCLUSION: In conclusion, our findings suggest that miR-145
expression is associated with OS in cancer patients and can serve as a
promising biomarker for monitoring prognosis.
